| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
From the Department of Internal Medicine III,* Kurume University School of Medicine, Kurume, Japan; the Department of Dermatology, Hokkaido University School of Medicine, Sapporo, Japan; the Department of Biochemistry, Hokuriku University, Kanazawa, Japan; the Division of Molecular and Cellular Immunology, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan; and the Departments of Medicine and Pathology, ¶ Yale University School of Medicine, New Haven, Connecticut
Angiogenesis, a process by which new vascular networks are formed from pre-existing capillaries, is required for tumors to grow, invade, and metastasize. Vascular endothelial growth factor (VEGF), a specific mitogen to endothelial cells, is a crucial factor for tumor angiogenesis. In this study, we investigated whether minodronate, a newly developed nitrogen-containing bisphosphonate, could inhibit melanoma growth and improve survival in nude mice by suppressing the VEGF signaling. We found here that minodronate inhibited melanoma growth and improved survival in nude mice by suppressing the tumor-associated angiogenesis and macrophage infiltration. Minodronate completely inhibited the VEGF-induced increase in DNA synthesis and tube formation in endothelial cells by suppressing NADPH oxidase-mediated reactive oxygen species generation and Ras activation. Furthermore, minodronate inhibited the VEGF-induced expression of intercellular adhesion molecule-1 and monocyte chemoattractant protein-1 in endothelial cells. Minodronate decreased DNA synthesis and increased apoptotic cell death of cultured melanoma cells as well. Our present study suggests that minodronate might suppress melanoma growth and improve survival in nude mice by two independent mechanisms; one is by blocking the VEGF signaling in endothelial cells, and the other is by inducing apoptotic cell death of melanoma. The present study provides a novel potential therapeutic strategy for the treatment of melanoma.
This article has been cited by other articles:
 |
|
 |
|
  T. Fujimura, S.-i. Yamagishi, S. Ueda, K. Fukami, R. Shibata, Y. Matsumoto, Y. Kaida, A. Hayashida, K. Koike, T. Matsui, et al. Administration of pigment epithelium-derived factor (PEDF) reduces proteinuria by suppressing decreased nephrin and increased VEGF expression in the glomeruli of adriamycin-injected rats Nephrol. Dial. Transplant., May 1, 2009; 24(5): 1397 - 1406. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Nakamura, S.-i. Yamagishi, T. Matsui, T. Yoshida, K. Takenaka, Y. Jinnouchi, Y. Yoshida, S.-i. Ueda, H. Adachi, and T. Imaizumi Pigment Epithelium-Derived Factor Inhibits Neointimal Hyperplasia after Vascular Injury by Blocking NADPH Oxidase-Mediated Reactive Oxygen Species Generation Am. J. Pathol., June 1, 2007; 170(6): 2159 - 2170. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Khamaisi, E. Regev, N. Yarom, B. Avni, E. Leitersdorf, I. Raz, and S. Elad Possible Association between Diabetes and Bisphosphonate-Related Jaw Osteonecrosis J. Clin. Endocrinol. Metab., March 1, 2007; 92(3): 1172 - 1175. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Roelofs, K. Thompson, S. Gordon, and M. J. Rogers Molecular mechanisms of action of bisphosphonates: current status. Clin. Cancer Res., October 15, 2006; 12(20): 6222s - 6230s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Inoue, T. Karashima, S. Fukata, A. Nomura, C. Kawada, A. Kurabayashi, M. Furihata, Y. Ohtsuki, and T. Shuin Effect of Combination Therapy with a Novel Bisphosphonate, Minodronate (YM529), and Docetaxel on a Model of Bone Metastasis by Human Transitional Cell Carcinoma Clin. Cancer Res., September 15, 2005; 11(18): 6669 - 6677. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Clezardin, F. H. Ebetino, and P. G.J. Fournier Bisphosphonates and Cancer-Induced Bone Disease: Beyond Their Antiresorptive Activity Cancer Res., June 15, 2005; 65(12): 4971 - 4974. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
